In vitro activity of a new echinocandin, LY303366, compared with those of amphotericin B and fluconazole against clinical yeast isolates

Antimicrobial Agents and Chemotherapy

Volumn 41, Issue 5, 1997, Pages 1156-1157

  Uzun, Ömrüm ^a   Kocagöz, Sesin ^a   Çetinkaya, Yeşim ^a   Arikan, Sevtap ^a   Ünal, Serhat ^a  

^a HACETTEPE UNIVERSITY   (Turkey)

Author keywords

[No Author keywords available]

Indexed keywords

AMPHOTERICIN B; ANIDULAFUNGIN; ECHINOCANDIN B DERIVATIVE; FLUCONAZOLE; NEW DRUG;

ANTIFUNGAL ACTIVITY; ARTICLE; CANDIDA ALBICANS; CANDIDA GLABRATA; CANDIDA KRUSEI; CANDIDA PARAPSILOSIS; CANDIDA TROPICALIS; COLONY FORMING UNIT; CONTROLLED STUDY; MINIMUM INHIBITORY CONCENTRATION; MYCOSIS; NONHUMAN; POWDER; PRIORITY JOURNAL; YEAST;

EID: 0030970811     PISSN: 00664804     EISSN: None     Source Type: Journal    
DOI: 10.1128/aac.41.5.1156     Document Type: Article

References (11)

1. Akova, M., H. E. Akalin, Ö. Uzun, and D. Gür. 1991. Emergence of Candida krusei infections after therapy of oropharyngeal candidiasis with fluconazole. Eur. J. Clin. Microbiol. Infect. Dis. 10:598-599. (Letter.)
2. Anaissie, E., V. Paetznick, and G. P. Bodey. 1991. Fluconazole susceptibility testing of Candida albicans: microtiter method that is independent of inoculum size, temperature, and time of reading. Antimicrob. Agents Chemother. 35:1641-1646.
3. Anaissie, E. J. 1992. Opportunistic mycoses in the immunocompromised host: experience at a cancer center and review. Clin. Infect. Dis. 14(Suppl. 1):S43-S53.
4. Anaissie, E. J., S. E. Vartivarian, D. Abi-Said, Ö. Uzun, H. Pinczowski, D. P. Konteyiannis, P. Khoury, K. Papadakis, A. Gardner, I.I. Raad, J. Gilbreath, and G. P. Bodey. 1996. Fluconazole versus amphotericin B in the treatment of hematogenous candidiasis: a matched cohort study. Am. J. Med. 101:170-176.
5. Banerjee, S. N., T. G. Emori, D. H. Culver, R. P. Gaynes, W. R. Jarvis, T. Horan, J. R. Edwards, J. Toison, T. Henderson, W. J. Martone, and the National Nosocomial Infections Surveillance System. 1991. Secular trends in nosocomial primary bloodstream infections in the United States. Am. J. Med. 91(Suppl. 3B):86S-89S.
6. Cameron, M. L., W. A. Schell, S. Bruch, J. A. Bartlett, H. A. Waskin, and J. R. Perfect. 1993. Correlation of in vitro fluconazole resistance of Candida isolates in relation to therapy and symptoms of individuals seropositive for human immunodeficiency virus type 1. Antimicrob. Agents Chemother. 37:2449-2453.
7. Hoban, D., A. Kabani, J. Karlowsky, M. Friesen, G. Harding, M. Turik, and G. Zhanel. 1996. Evaluation of in vitro activity of a new echinocandin, LY303366 against systemic isolates of Candida spp. and Cryptococcus neoformans, abstr. F47, p. 108. In Abstracts of the 36th Interscience Conference on Antimicrobial Agents and Chemotherapy. American Society for Microbiology, Washington, D.C.
8. National Committee for Clinical Laboratory Standards. 1995. Reference method for broth dilution antifungal susceptibility testing of yeasts. Tentative standard. National Committee for Clinical Laboratory Standards, Villanova, Pa.
9. Pfaller, M. A., S. Messer, and S. Coffman. 1996. In vitro susceptibility of Candida blood stream isolates to a new echinocandin derivative, LY303366, and comparative antifungal agents, abstr. F48, p. 108. In Abstracts of the 36th Interscience Conference on Antimicrobial Agents and Chemotherapy. American Society for Microbiology, Washington, D.C.
10. Rex, J. H., J. E. Bennett, A. M. Sugar, P. G. Pappas, C. M. van der Horst, J. E. Edwards, R. G. Washburn, W. M. Scheld, A. W. Karchmer, A. P. Dine, M. J. Levenstein, and C. D. Webb. 1994. A randomized trial comparing fluconazole with amphotericin B for the treatment of candidemia in patients without neutropenia. N. Engl. J. Med. 331:1325-1330.
11. Wingard, J. R., W. G. Merz, M. G. Rinaldi, T. R. Johnson, J. E. Karp, and R. Saral. 1991. Increase in Candida krusei infection among patients with bone marrow transplantation and neutropenia treated prophylactically with fluconazole. N. Engl. J. Med. 325:1274-1277.